GlassScriptPhysician profile
Aditya Sood
NPI 1871934448
$3,959.31
in general payments reported to CMS, 2019-2025
24 companies · $724 in 2025
The $724 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $224 · 2021: $346 · 2022: $926 · 2023: $833 · 2024: $618 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $725.71 | 2021-2025 | Cobalt Dr Mri Surescan, Onyx Frontier, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $594.39 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $377.09 | 2023-2025 | |
| Biotronik INC. | $347.04 | 2020-2025 | Selectra, Biomonitor |
| Pfizer INC. | $342.51 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $277.50 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $197.50 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $160.51 | 2021-2024 | Farxiga |
| Inari Medical, INC. | $136.68 | 2022 | |
| Novo Nordisk INC | $110.71 | 2024-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $102.24 | 2020-2024 | Xarelto |
| Abiomed | $88.70 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $88.44 | 2022-2023 | Verquvo |
| Vital Connect, INC | $61.15 | 2024 | Vitalpatch Rtm |
| Boston Scientific Corporation | $52.45 | 2023-2025 | Cds - Mct/Cem Monitoring, Bodyguardian |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $50.98 | 2022-2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $46.30 | 2025 | Amvuttra, Onpattro |
| Cardiva Medical, INC. | $34.65 | 2025 | Cardiva Vascade 6/7f Vcs |
| Edwards Lifesciences Corporation | $34.57 | 2019-2022 | |
| Cvrx, INC. | $32.99 | 2022-2024 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $28.37 | 2023 | Opsumit, Uptravi |
| Angiodynamics, INC. | $25.21 | 2019 | |
| Lantheus Medical Imaging, INC. | $24.44 | 2024 | |
| Amarin Pharma, INC. | $19.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.